Dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate - Generic Drug Details

What are the generic drug sources for dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate and what is the scope of patent protection?

Dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate is the generic ingredient in two branded drugs marketed by B Braun and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate

US Patents:	0
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	56
DailyMed Link:	dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate at DailyMed

Recent Clinical Trials for dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nextrast, Inc.	PHASE1
Mario Negri Institute for Pharmacological Research	PHASE3
French Innovative Leukemia Organisation	PHASE2

See all dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate clinical trials

Pharmacology for dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate

Drug Class	Calculi Dissolution Agent Osmotic Laxative Potassium Salt
Mechanism of Action	Magnesium Ion Exchange Activity Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Inhibition Small Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion

Anatomical Therapeutic Chemical (ATC) Classes for dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate

A12BA	Potassium
A12B	POTASSIUM
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

A12CC	Magnesium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

US Patents and Regulatory Information for dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER	dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate	INJECTABLE;INJECTION	019025-001	Dec 27, 1984		DISCN	No	No
B Braun	ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER	dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium acetate	INJECTABLE;INJECTION	019873-001	Jun 10, 1993		RX	No	No

Market Dynamics and Financial Trajectory for Selected Pharmaceutical Drugs

Last updated: March 6, 2026

What Are the Current Market Trends for These Electrolyte and Glucose-Based Drugs?

The market for dextrose, magnesium chloride, potassium chloride, potassium phosphate dibasic, and sodium acetate is molecularly linked to the global electrolyte and glucose infusion segments. The demand stems from hospitals, outpatient clinics, and home healthcare, driven by increasing prevalence of dehydration, electrolyte imbalances, and metabolic disorders.

Key market drivers include:

• Growth in chronic diseases requiring intravenous therapy.
• Rising incidence of dehydration due to heatwaves, infections, and gastrointestinal conditions.
• Expansion of healthcare infrastructure, especially in emerging markets.
• Advances in formulation technologies facilitating better stability and shelf life.

In 2022, the global electrolyte solutions market was valued at approximately USD 6.5 billion, with an annual growth rate of 5.8%, projected to reach USD 9.3 billion by 2027 [1].

The glucose solution segment, notably dextrose, forms a significant portion, representing about 30-35% of total electrolyte and glucose solution revenues.

How Do Market Players and Competition Shape the Landscape?

Major pharmaceutical companies dominate: B. Braun and Fresenius Kabi are key players, offering a comprehensive portfolio of electrolyte and glucose infusions. Established players hold over 60% of market share, with local manufacturers gaining ground in emerging markets.

Generic manufacturers benefit from patent expirations and commoditized formulations, leading to price erosion, especially in price-sensitive regions.

Private label and regional brands account for nearly 20% of sales in Asia-Pacific and Latin America, where reducing healthcare costs is a priority.

What Are the Regulatory and Supply Chain Impacts?

Regulatory agencies such as the FDA and EMA enforce strict standards for manufacturing, sterility, and stability to ensure patient safety, impacting costs and time-to-market.

Supply chains face disruptions from geopolitical tensions and raw material shortages, notably for potassium compounds sourced from specific regions. This creates pricing volatility and supply security concerns.

What Is the Financial Trajectory Based on Recent Data?

The combined global market for these electrolyte drugs is expected to grow at a compounded annual growth rate (CAGR) of 5.2% from 2022 to 2030. The forecasted USD 9.5 billion market in 2030 reflects ongoing demand and expanding applications.

Profit margins vary: Brand-name electrolytes average 20-25%, while generics operate around 10-15%. Market entrants focusing on cost-efficient manufacturing and supply chain optimization may see improved margins.

Regions differ:

• North America: USD 2.5 billion (2022), high reimbursement rates, stable demand.
• Europe: USD 1.9 billion, market maturity, regulatory barriers slow growth.
• Asia-Pacific: USD 1.4 billion, fastest growth, driven by healthcare infrastructure expansion.
• Latin America and Middle East: USD 0.7 billion, growth driven by increasing healthcare access.

How Do Formulation and Delivery Method Affect Market Trajectory?

Intravenous solutions dominate the market, representing over 80% of sales, with fluid balance management as primary application. Innovations in pre-filled syringes and concentration options strengthen their market share.

Oral formulations for certain indications provide lower-margin alternatives but are limited to specific patient groups.

Summary of Market and Financial Data

Region	2022 Market Value	CAGR (2022-2030)	Key Notes
North America	USD 2.5 billion	4.8%	Reimbursement incentives, mature market
Europe	USD 1.9 billion	4.5%	Slow growth, high regulatory standards
Asia-Pacific	USD 1.4 billion	6.2%	Rapid expansion, infrastructure growth
Latin America/Middle East	USD 0.7 billion	6.0%	Emerging markets, increasing demand

What Are the Risks and Opportunities?

Risks include raw material price volatility, supply disruptions, and regulatory delays. Opportunities lie in developing stabilized formulations, expanding into underpenetrated markets, and integrating with advanced infusion delivery systems.

Key Takeaways

• Market size is expected to reach USD 9.5 billion by 2030, with a CAGR of 5.2%.
• North America remains the largest market; Asia-Pacific offers the highest growth potential.
• Major players maintain dominance through established brands; generics and regional brands gain importance.
• Regulatory compliance and supply chain resilience drive operational costs.
• Innovation focuses on formulations and delivery mechanisms to capture incremental market share.

FAQs

1. What is the primary driver of growth for electrolyte solutions?
Rising prevalence of dehydration, electrolyte imbalances, and increasing use in clinical settings.

2. How do patent expirations affect market competition?
They enable generic manufacturers to enter the market, intensifying price competition and eroding margins.

3. What regional factors influence market growth?
Healthcare infrastructure development, regulatory frameworks, raw material availability, and economic development.

4. Are there emerging applications for these drugs?
Yes; for example, use in sports medicine, critical care, and in outpatient settings with home infusion therapy.

5. How is technology affecting formulation and delivery?
Advancements enable more stable, ready-to-use solutions and smarter infusion devices, expanding usability and safety.

References

1. MarketsandMarkets. (2022). Electrolyte solutions market by type, application, and region: Global forecast to 2027.